Daniel Acuña, the lead author of this crucial study, is an associate professor in the Department of Computer Science at the University of Colorado. His personal experiences have illustrated the pressing need for such a tool. Acuña receives frequent emails from so-called editors promising to publish his research for a hefty price, which often leads to the alarming realization that many of these journals are essentially scams. He coined the term “predatory journals” to describe how these entities prey on scientists, luring them with promises of instant publication without the rigors of genuine peer review.

The evolution of the predatory journal phenomenon can be traced back to 2009 when Jeffrey Beall, a librarian at CU Denver, first articulated the concept. This growing trend is particularly concerning given the pressures placed on researchers worldwide, especially in countries with emerging scientific institutions like China, India, and Iran. Here, researchers are often required to publish frequently, leading them to vulnerable positions where predatory journals exploit their need to contribute to scholarly literature without the necessary safeguards in place.

In recognizing the scale of the issue, Acuña’s team developed an AI-driven system that scrutinizes an extensive array of journals. The tool evaluates various factors that might indicate a publication’s legitimacy, such as the presence of an editorial board consisting of established researchers and the frequency of grammatical errors on the journal’s website. The need for such a solution is underscored by the ease with which predatory journals can appear and disappear. Once flagged, these journals can simply change their names and web addresses in a never-ending cycle that researchers find difficult to track.

Despite the multifaceted challenges posed by predatory journals, Acuña asserts that the AI tool is not a perfect solution and is intended to supplement, not replace, human expertise. The nuanced judgment required to assess a journal’s credibility is still best suited to seasoned academics who can better evaluate the context and quality of the scientific outputs on offer. Acuña’s belief in human oversight is essential in ensuring that legitimate journals are not mistakenly categorized as predatory.

Moreover, as scientific legitimacy comes under scrutiny, the implications of unchecked publication practices are dire. The foundation of scientific progress relies on the accuracy and reliability of prior research; without stringent controls, the very structure upon which further scientific inquiry is built could easily crumble, leading to a significant erosion of trust in research as a whole. This urgency drives scientists and institutions to act decisively against the proliferation of fraudulent journals.

The study’s findings indicated that among the nearly 15,200 open-access journals analyzed, the AI initially flagged more than 1,400 as potentially dubious. Subsequent human reviews returned an estimated error rate, revealing approximately 350 journals erroneously labeled as problematic. Nevertheless, this resulted in over 1,000 journals that warranted further investigation, affirming the AI’s utility as a prescreening tool to help researchers sift through the vast landscape of online publications more efficiently.

Acuña’s team did not wish to create an opaque “black box” model like many other AI tools; they aimed for transparency in their design. Users can understand the rationale behind the tool’s assessments, an aspect that adds to the overall reliability of the system. Their research revealed that questionable journals frequently publish a high volume of articles and possess authors with numerous affiliations, alongside a tendency for authors to excessively cite their own work rather than integrating broader scientific discourse.

Although the AI system is not yet publicly available, there are plans for it to be deployed in universities and by publishing companies. Acuña envisions this tool as an essential resource in maintaining the integrity of scientific research, effectively acting as a “firewall for science.” Such a mechanism could ensure that the data informing future discoveries is solid and dependable, helping to fortify the scientific community against the detrimental effects of bad data.

To put the significance of the findings into perspective, Acuña makes a relatable analogy to the way we approach technology. Just as consumers come to expect updates and bug fixes with new smartphones, the field of science must similarly adapt, recognizing the need for continual refinements in its publishing practices. Through innovations like Acuña’s AI platform, the academic community can strive to reclaim the integrity that is crucial to scholarly advancement.

With the potential to reach an audience eager for solutions to a pervasive problem, the research encapsulates the challenges posed by predatory journals and the efforts being made to combat them using advanced technology. These developments signal a hopeful turn in the ongoing battle for credibility in academic publishing. As universities and research institutions grapple with this complex issue, the AI platform represents a step toward reclaiming control and ensuring that the foundations of science remain sound.

The urgency of safeguarding against disreputable publications has never been greater. As science increasingly relies on vast networks of information, the potential for misleading or fraudulent research to undermine years of progress looms large. The challenges posed by predatory journals must be addressed methodically and rigorously, as the validity of scientific research—essential for societal advancement—hangs in the balance. Protecting the sanctity of academic publishing is not merely an academic endeavor but a vital necessity for preserving trust in the scientific enterprise.

In conclusion, Acuña and his team’s efforts not only highlight the critical need for vigilance in the face of predatory practices but also showcase how cutting-edge technology can be harnessed effectively to combat these challenges. Their work represents a clear call to both the scientific community and the public to remain aware of the complexities of academic publishing and encourages further discourse on the mechanisms that can safeguard the future of research integrity.

Subject of Research: Identification of questionable scientific journals using artificial intelligence.
Article Title: Estimating the predictability of questionable open-access journals.
News Publication Date: August 27, 2023.
Web References: Science Advances
References: Directory of Open Access Journals
Image Credits: University of Colorado Boulder.

Keywords

AI, predatory journals, scientific publishing, research integrity, academic reputation, peer review.

In recent years, medical writing services have become an influential yet controversial element within scientific manuscript preparation, particularly in specialized fields such as hematology. Originally intended to streamline the production of complex research manuscripts, these services now prompt ethical concerns due to potential conflicts of interest and the subtle ways industry influence might permeate scientific literature. A groundbreaking analysis recently published in BMC Cancer brings to light the prevalence and characteristics of medical writing in review articles focusing on hematological malignancies, unveiling critical insights into the involvement of medical writers and their funding sources.

Despite the far-reaching use of medical writing in oncology and malignant hematology clinical trials, its presence in review articles — scholarly works that synthesize and interpret existing research — remains under-examined. This new research sought to fill this gap by systematically examining review articles across a comprehensive five-year span from 2019 to 2023, targeting the top ten hematology journals based on their impact factors. The study’s scope included a variety of review formats such as narrative and systematic reviews, clinical guidelines, and articles offering clinical advice, while carefully excluding basic science and benign hematology studies.

Within a dataset of 663 analyzed review articles, the researchers found that a relatively small percentage—5.7%—disclosed the involvement of medical writing assistance. Notably, none of these articles credited the medical writers as co-authors, raising questions about transparency and acknowledgment within scientific publishing conventions. Some journals, however, stood out due to markedly higher medical writing involvement, with one particular journal showing a disclosure rate as high as 21%, suggesting variable editorial policies and cultural norms around medical writing acknowledgement across hematology publications.

An examination of the funding sources behind medical writing revealed that a vast majority—approximately 89%—were supported by industry sponsors. This finding fuels ongoing debates around the impartiality of scientific manuscripts, especially when writers are funded by pharmaceutical companies with vested interests in the review outcomes. The dominant presence of industry funding for medical writing assistance amplifies concerns regarding potential biases, subtle spin, and the shaping of medical narratives that may favor particular treatments or drugs.

The subfield of plasma cell malignancy reviews demonstrated the highest utilization of medical writing at 11%, suggesting that certain topics within hematological malignancies attract disproportionate levels of industry-supported writing involvement. Since plasma cell disorders include high-profile diseases such as multiple myeloma, this trend could reflect commercial priorities and intense drug development competition within this therapeutic area.

Financial conflicts of interest (CoI) among article authors emerged as a closely intertwined issue in the study’s findings. Specifically, 28% of first authors and 34% of last authors were found to have direct financial ties, such as industry payments, associated with the reviewed topics. The prevalence skyrocketed to 71% in reviews focused on specific drugs, indicating an alarmingly high overlap between author financial engagements and the subject matter of their reviews. These statistics underscore the complexity surrounding unbiased evidence synthesis in hematology, suggesting that financial relationships might influence not only clinical trials but also literature that guides clinical practice and policy.

Only a single journal among those surveyed maintained explicit policies regulating medical writing in review articles, pointing to a significant policy gap in editorial standards. This scarcity of formalized guidelines raises concerns about managing transparency, accountability, and ethical norms in scientific publishing where medical writing assistance is utilized. Without consistent editorial oversight, inconsistent disclosure practices and potential conflicts may persist unchecked.

The nuanced ethical landscape surrounding medical writing extends beyond mere acknowledgment of assistants to the broader implications for scientific integrity. The lack of inclusion of medical writers as co-authors may obscure the extent of their contributions, while funding injections by pharmaceutical companies reveal an intersection where scientific communication converges with commercial interests. This delicate balance requires vigilant scrutiny to preserve trust within the scientific community and maintain rigorous standards of impartiality.

Drawing attention to medical writing within hematology review literature illuminates a subtle but impactful mechanism through which industry influence can permeate evidence synthesis, clinical guidelines, and consensus statements. The ramifications are profound, as reviews serve as foundational references for clinicians, researchers, policymakers, and ultimately patients. Therefore, understanding the prevalence, funding, and authorship dynamics behind these critical scholarly works is essential for advancing transparency and objectivity in hematology research dissemination.

The study’s revelations enrich ongoing discourse on the ethics of medical writing and conflict of interest disclosure, echoing broader concerns across biomedical publishing about ghostwriting, transparency, and the role of commercial sponsorship. By documenting discrete patterns in a focused field, the research invites an assessment of current editorial practices and encourages adoption of clearer policies governing medical writing contributions and conflict of interest management.

Beyond the hematology sphere, these findings resonate with challenges faced across diverse medical specialties where pharmaceutical industry funding and medical writing play pivotal roles. The insights gained here therefore have implications for the development of universal best practices designed to safeguard scientific scrutiny and reinforce publication integrity on a global scale.

In conclusion, this comprehensive analysis spotlights a modest yet significant presence of medical writing in malignant hematology review articles, driven predominantly by industry sponsorship. The high incidence of author financial conflicts of interest in drug-specific reviews signals a compelling need to re-evaluate editorial approaches and fortify disclosure requirements. As review articles influence clinical decision-making and healthcare guidelines, ensuring transparent, unbiased authorship and funding practices is imperative to uphold trust in scientific literature.

Ongoing vigilance and enhanced editorial frameworks could pave the way for harmonized standards on medical writing disclosure, conflict of interest management, and authorship recognition. These measures would empower researchers, clinicians, and readers alike to critically appraise the provenance of information shaping hematology and beyond. As biomedical science advances at an unprecedented pace, fostering ethical rigor in the narration of evidence remains a cornerstone for meaningful, trustworthy knowledge dissemination.

Subject of Research: Prevalence and characteristics of medical writing in malignant hematology review articles and its relationship with authors’ financial conflicts of interest.

Article Title: Prevalence of medical writing in hematological malignancy review articles

Article References:
Vaquera-Alfaro, H.A., Nasrollahi, E., Mangala, Y.O. et al. Prevalence of medical writing in hematological malignancy review articles. BMC Cancer 25, 720 (2025). https://doi.org/10.1186/s12885-025-14137-5

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14137-5